IBRX News

Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Connect

Pomerantz LLP Advises Shareholders of Class Action Filing Involving ImmunityBio, Inc. – IBRX

IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - IBRX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

ImmunityBio, Inc. Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit